Gricar acquires 100% of Farmaceutical Group, plans 20% workforce boost
What's the deal? Synergica Srl, a holding company controlled by Italian entrepreneur Gian Marco Carenzi and owner of Gricar Chemical, has acquired 100% of Farmaceutical Group, a contract manufacturer in the nutraceutical sector. The deal aims to deepen industrial integration between the two companies, expanding production capacity, technological capabilities, and product development for the nutraceutical and medical markets.
The acquisition was advised by Milan-based Studio TLA on fiscal, legal, and financial matters. Emanuele Stocchero, Farmaceutical Group's former owner, will stay on as an administrator.
Why now? The nutraceutical contract manufacturing market is growing fast, and Gricar sees an opportunity to scale up before competitors consolidate. The industrial plan includes expanding production facilities, opening a new unit dedicated to liquid products, and introducing technologies the group currently lacks.
The combined entity will also gain flexibility to route production across different units depending on batch size and industrial needs — a competitive edge in contract manufacturing, where clients demand speed and customisation.
What could go wrong? Integrating two manufacturing operations is never simple. Merging production lines, technology stacks, and corporate cultures carries execution risk. A planned 20% increase in headcount adds hiring and training pressure at a time when skilled manufacturing talent is in short supply across Europe.
The signal: This deal reflects a broader consolidation trend in European nutraceutical manufacturing, where smaller players are combining to achieve scale and vertical integration. "The integration with Farmaceutical Group will allow us to increase efficiency and production capacity without losing flexibility," Carenzi said. As demand for supplements and functional health products keeps climbing, expect more mid-market M&A in this space.
Read more: corrierenazionale.it
